SEARCH:   Advanced

Blood, 15 January 2009, Vol. 113, No. 3, pp. 604-611. Prepublished online as a Blood First Edition Paper on October 9, 2008; DOI 10.1182/blood-2008-02-136903. This Article Full Text Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2008-02-136903v1 113/3/604    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Al Tabaa, Y. Articles by Vendrell, J.-P. Search for Related Content PubMed PubMed Citation Articles by Al Tabaa, Y. Articles by Vendrell, J.-P. Related Collections Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells Yassine Al Tabaa1, Edouard Tuaillon1, Karine Bollore1, Vincent Foulongne1, Gael Petitjean1, Jean-Marie Seigneurin2, Christophe Duperray3, Claude Desgranges4,5, and Jean-Pierre Vendrell1,3 1 Department of Virology, University Medical Center, Montpellier; 2 Department of Virology, University Medical Center, Grenoble; 3 Inserm U847, Montpellier; 4 Institut Cochin, Université René Descartes, Centre National de la Recherche Scientifique (Unite Mixte de Recherche 8104), Paris; and 5 Inserm U567, Paris, France The Epstein-Barr virus (EBV) causes infectious mononucleosis, establishes latency in resting memory B lymphocytes, and is involved in oncogenesis through poorly understood mechanisms. The EBV lytic cycle is initiated during plasma cell differentiation by mRNAs transcripts encoded by BZLF1, which induce the synthesis of EBV proteins such as the immediate-early antigen ZEBRA and the late membrane antigen gp350. Therefore, we assessed the capacity of circulating EBV-infected B lymphocytes from healthy EBV-seropositive subjects to enter and complete the EBV lytic cycle. Purified B lymphocytes were polyclonally stimulated and BZLF1- or gp350-secreting cells (BZLF1-SCs or gp350-SCs) were enumerated by ELISpot assays. The number of BZLF1-SCs ranged from 50 to 480/107 lymphocytes (median, 80; 25th-75th percentiles, 70-150) and gp350-SCs from 10 to 40/107 lymphocytes (median, 17; 25th-75th percentiles, 10-20). gp350-SCs represented only 7.7% to 28.6% of BZLF1-SCs (median, 15%; 25th-75th percentiles, 10.5%-20%). This EBV functional reservoir was preferentially restricted to plasma cells derived from CD27+ IgD– memory B lymphocytes. In 9 of 13 subjects, EBV DNA quantification in B-cell culture supernatants gave evidence of completion of EBV lytic cycle. These results demonstrate that EBV proteins can be secreted by EBV-infected B lymphocytes from healthy carriers, a majority generating an abortive EBV lytic cycle and a minority completing the cycle. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Brady, H. J. Whiteman, L. C. Spender, and P. J. Farrell Downregulation of RUNX1 by RUNX3 Requires the RUNX3 VWRPY Sequence and Is Essential for Epstein-Barr Virus-Driven B-Cell Proliferation J. Virol., July 1, 2009; 83(13): 6909 - 6916. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020